Noninvasive detection of lung cancer by analysis of exhaled breath

BMC Cancer - Tập 9 Số 1 - 2009
Amel Bajtarevic1,2, Clemens Ager1,2, Martin Pienz1,2, Martin Klieber1,2, Konrad Schwarz1,2, Magdalena Ligor1,2,3, Tomasz Ligor1,2,3, Wojciech Filipiak1,2, H. Denz1,4, Michael Fiegl1,4, Wolfgang Hilbe5, Wolfgang Weiß6, Peter Lukáš6, Herbert Jamnig4, Martin Hackl4, Alfred Haidenberger7, Bogusław Buszewski1,3, Wolfram Miekisch1,8, Jochen K. Schubert1,8, Anton Amann1,2
1Breath Research Unit of the Austrian Academy of Sciences, Dornbirn, Austria
2Department of Operative Medicine, Innsbruck Medical University, Innsbruck, Austria
3Faculty of Chemistry, Nicolaus Copernicus University, Toruñ, Poland
4Landeskrankenhaus Natters, Natters, Austria
5Univ.-Klinik für Innere Medizin 5 (Hämatologie und Onkologie), Innsbruck Medical University, Innsbruck, Austria
6Universitätsklinik für Strahlentherapie-Radioonkologie Innsbruck, Innsbruck Medical University, Innsbruck, Austria
7Institution of Radio-Oncology, LKH Vöcklabruck, Vöcklabruck, Austria
8Department of Anaesthesiology and Intensive Care, University of Rostock, Rostock, Germany

Tóm tắt

Abstract Background Lung cancer is one of the leading causes of death in Europe and the western world. At present, diagnosis of lung cancer very often happens late in the course of the disease since inexpensive, non-invasive and sufficiently sensitive and specific screening methods are not available. Even though the CT diagnostic methods are good, it must be assured that "screening benefit outweighs risk, across all individuals screened, not only those with lung cancer". An early non-invasive diagnosis of lung cancer would improve prognosis and enlarge treatment options. Analysis of exhaled breath would be an ideal diagnostic method, since it is non-invasive and totally painless. Methods Exhaled breath and inhaled room air samples were analyzed using proton transfer reaction mass spectrometry (PTR-MS) and solid phase microextraction with subsequent gas chromatography mass spectrometry (SPME-GCMS). For the PTR-MS measurements, 220 lung cancer patients and 441 healthy volunteers were recruited. For the GCMS measurements, we collected samples from 65 lung cancer patients and 31 healthy volunteers. Lung cancer patients were in different disease stages and under treatment with different regimes. Mixed expiratory and indoor air samples were collected in Tedlar bags, and either analyzed directly by PTR-MS or transferred to glass vials and analyzed by gas chromatography mass spectrometry (GCMS). Only those measurements of compounds were considered, which showed at least a 15% higher concentration in exhaled breath than in indoor air. Compounds related to smoking behavior such as acetonitrile and benzene were not used to differentiate between lung cancer patients and healthy volunteers. Results Isoprene, acetone and methanol are compounds appearing in everybody's exhaled breath. These three main compounds of exhaled breath show slightly lower concentrations in lung cancer patients as compared to healthy volunteers (p < 0.01 for isoprene and acetone, p = 0.011 for methanol; PTR-MS measurements). A comparison of the GCMS-results of 65 lung cancer patients with those of 31 healthy volunteers revealed differences in concentration for more than 50 compounds. Sensitivity for detection of lung cancer patients based on presence of (one of) 4 different compounds not arising in exhaled breath of healthy volunteers was 52% with a specificity of 100%. Using 15 (or 21) different compounds for distinction, sensitivity was 71% (80%) with a specificity of 100%. Potential marker compounds are alcohols, aldehydes, ketones and hydrocarbons. Conclusion GCMS-SPME is a relatively insensitive method. Hence compounds not appearing in exhaled breath of healthy volunteers may be below the limit of detection (LOD). PTR-MS, on the other hand, does not need preconcentration and gives much more reliable quantitative results then GCMS-SPME. The shortcoming of PTR-MS is that it cannot identify compounds with certainty. Hence SPME-GCMS and PTR-MS complement each other, each method having its particular advantages and disadvantages. Exhaled breath analysis is promising to become a future non-invasive lung cancer screening method. In order to proceed towards this goal, precise identification of compounds observed in exhaled breath of lung cancer patients is necessary. Comparison with compounds released from lung cancer cell cultures, and additional information on exhaled breath composition in other cancer forms will be important.

Từ khóa


Tài liệu tham khảo

Chan HP, Lewis C, Thomas PS: Exhaled breath analysis: novel approach for early detection of lung cancer. Lung Cancer. 2009, 63 (2): 164-168. 10.1016/j.lungcan.2008.05.020.

Corradi M, Poli D, Selis L, Carbognani P, Acampa O, Iavicoli S, Rusca M, Mutti A: [Volatile hydrocarbons in exhaled air: preliminary data on the characteristic profile associated with lung tumors]. G Ital Med Lav Ergon. 2003, 25 (Suppl 3): 59-60.

Di Natale C, Macagnano A, Martinelli E, Paolesse R, D'Arcangelo G, Roscioni C, Finazzi-Agro A, D'Amico A: Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron. 2003, 18 (10): 1209-1218. 10.1016/S0956-5663(03)00086-1.

Dragonieri S, Annema JT, Schot R, Schee van der MP, Spanevello A, Carratu P, Resta O, Rabe KF, Sterk PJ: An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer. 2009, 64 (2): 166-170. 10.1016/j.lungcan.2008.08.008.

Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenberg J, Kloss R, Maxfield RA, Munawar MI, Pass HI, et al: Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark. 2007, 3 (2): 95-109.

Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, et al: Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta. 2008, 393 (2): 76-84. 10.1016/j.cca.2008.02.021.

Phillips M, Cataneo RN, Cummin AR, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA, Rom WN: Detection of lung cancer with volatile markers in the breath. Chest. 2003, 123 (6): 2115-2123. 10.1378/chest.123.6.2115.

Wehinger A, Schmid A, Mechtcheriakov S, Ledochowski M, Grabmer C, Gastl G, Amann A: Lung cancer detection by proton transfer reaction mass spectrometric analysis of human breath gas. Int J Mass Spec. 2007, 265: 49-59. 10.1016/j.ijms.2007.05.012.

Buszewski B, Kesy M, Ligor T, Amann A: Human exhaled air analytics: biomarkers of diseases. Biomed Chromatogr. 2007, 21 (6): 553-566. 10.1002/bmc.835.

Manolis A: The diagnostic potential of breath analysis. Clin Chem. 1983, 29 (1): 5-15.

Miekisch W, Schubert JK, Noeldge-Schomburg GF: Diagnostic potential of breath analysis--focus on volatile organic compounds. Clin Chim Acta. 2004, 347 (1-2): 25-39. 10.1016/j.cccn.2004.04.023.

Amann A, Smith D, eds: Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. 2005, Singapore: World Scientific

Risby T: Current status of clinical breath analysis. Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Edited by: Amann A, Smith D. 2005, Singapore: World Scientific, 251-265.

Amann A, Spanel P, Smith D: Breath analysis: the approach towards clinical applications. Mini reviews in Medicinal Chemistry. 2007, 7: 115-129. 10.2174/138955707779802606.

Amann A, Poupart G, Telser S, Ledochowski M, Schmid A, Mechtcheriakov S: Applications of breath gas analysis in medicine. Int J Mass Spectrometry. 2004, 239: 227-233. 10.1016/j.ijms.2004.08.010.

Erhart S, Amann A, Karall D, Edlinger G, Haberlandt E, Schmid A, Filipiak W, Mochalski P, Rostasy K, Scholl-Bürgi S: 3-Heptanone as a potential new marker for valproic acid therapy. J Breath Res. 2009, 3: 016004-10.1088/1752-7155/3/1/016004. (016006 pp)

Schubert J, Miekisch W, Geiger K: Exhaled breath markers in ARDS. Lung Biology in Health and Disease Disease Markers in Exhaled Breath. Edited by: Marczin N, Kharitonov S. 2003, New York: Marcel Dekker, 363-380.

Schubert J, Miekisch W, Nöldge-Schomburg G: VOC breath markers in critically ill patients: potentials and limitations. Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Edited by: Amann A, Smith D. 2005, Singapore: World Scientific, 267-292.

Pabst F, Miekisch W, Fuchs P, Kischkel S, Schubert JK: Monitoring of oxidative and metabolic stress during cardiac surgery by means of breath biomarkers: an observational study. J Cardiothorac Surg. 2007, 2: 37-10.1186/1749-8090-2-37.

Karl T, Prazeller P, Mayr D, Jordan A, Rieder J, Fall R, Lindinger W: Human breath isoprene and its relation to blood cholesterol levels: new measurements and modeling. J Appl Physiol. 2001, 91 (2): 762-770.

Amann A, Telser S, Hofer L, Schmid A, Hinterhuber H: Exhaled breath as a biochemical probe during sleep. Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Edited by: Amann A, Smith D. 2005, Singapore: World Scientific, 305-316.

King J, Kupferthaler A, Unterkofler K, Koc H, Teschl S, Miekisch W, Schubert J, Hitnerhuber H, Amann A: Isoprene and acetone concentration profiles during exercise at an ergometer. J Breath Res. 2009, s3: 027006-10.1088/1752-7155/3/2/027006. (02701pp)

Ligor T, Szeliga J, Jackowski M, Buszewski B: Preliminary study of volatile organic compounds from breath and stomach tissue by means of solid phase microextraction and gas chromatography-mass spectrometry. J Breath Research. 2007, 1 (1): 016001-10.1088/1752-7155/1/1/016001.

Chen X, Xu F, Wang Y, Pan Y, Lu D, Wang P, Ying K, Chen E, Zhang W: A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. Cancer. 2007, 110 (4): 835-844. 10.1002/cncr.22844.

Filipiak W, Sponring A, Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J: Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro. Cancer Cell Int. 2008, 8 (1): 17-10.1186/1475-2867-8-17.

Sponring A, Filipiak W, Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J: Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Res. 2009, 29 (1): 419-426.

Phillips M, Cataneo RN, Ditkoff BA, Fisher P, Greenberg J, Gunawardena R, Kwon CS, Rahbari-Oskoui F, Wong C: Volatile markers of breast cancer in the breath. Breast J. 2003, 9 (3): 184-191. 10.1046/j.1524-4741.2003.09309.x.

Phillips M, Gleeson K, Hughes JM, Greenberg J, Cataneo RN, Baker L, McVay WP: Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet. 1999, 353 (9168): 1930-1933. 10.1016/S0140-6736(98)07552-7.

Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O, Balbi B, Bianchi L, Rusca M, Mutti A: Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res. 2005, 6 (1): 71-10.1186/1465-9921-6-71.

Schubert J, Miekisch W, Birken T, Geiger K, Nöldge-Schomburg G: Impact of inspired substance concentrations onto results of breath analysis in mechanically ventilated patients. Biomarkers. 2005, 10: 138-152. 10.1080/13547500500050259.

Schubert JK, Miekisch W, Geiger K, Noldge-Schomburg GF: Breath analysis in critically ill patients: potential and limitations. Expert Rev Mol Diagn. 2004, 4 (5): 619-629. 10.1586/14737159.4.5.619.

Ligor T, Ligor M, Amann A, Ager C, Bachler M, Dzien A, Buszewski B: The analysis of healthy volunteers' exhaled breath by the use of solid-phase microextraction and GC-MS. J Breath Research. 2008, 2: 046006-10.1088/1752-7155/2/4/046006.

Kushch I, Arendacka B, Stolc S, Mochalski P, Filipiak W, Schwarz K, Schwentner L, Schmid A, Dzien A, Lechleitner M, et al: Breath isoprene - aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. Clin Chem Lab Med. 2008, 46: 1011-1018. 10.1515/CCLM.2008.181.

Kushch I, Schwarz K, Schwentner L, Baumann B, Dzien A, Schmid A, Unterkofler K, Gastl G, Španel P, Smith D, et al: Compounds enhanced in a mass spectrometric profile of smokers' exhaled breath versus non-smokers as determined in a pilot study using PTR-MS. J Breath Res. 2008, 2: 026002-10.1088/1752-7155/2/2/026002.

Ligor M, Ligor T, Bajtarevic A, Ager C, Pienz M, Klieber M, Denz H, Fiegl M, Hilbe W, Weiss W, et al: Determination of volatile organic compounds appearing in exhaled breath of lung cancer patients by solid phase microextraction and gas chromatography mass spectrometry. Clin Chem Lab Med. 2009, 47: 550-560. 10.1515/CCLM.2009.133.

Machado RF, Laskowski D, Deffenderfer O, Burch T, Zheng S, Mazzone PJ, Mekhail T, Jennings C, Stoller JK, Pyle J, et al: Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med. 2005, 171 (11): 1286-1291. 10.1164/rccm.200409-1184OC.

Smith D, Spanel P: Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. Mass Spectrometry Reviews. 2005, 24 (5): 661-700. 10.1002/mas.20033.

Spanel P, Dryahina K, Smith D: Acetone, ammonia and hydrogen cyanide in exhaled breath of several volunteers aged 4-83 years. J Breath Research. 2007, 1 (1): 011001-10.1088/1752-7155/1/1/011001.

Spanel P, Dryahina K, Smith D: The concentration distributions of some metabolites in the exhaled breath of young adults. J Breath Research. 2007, 1 (2): 026001-10.1088/1752-7155/1/2/026001.

Phillips M, Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo RN: Variation in volatile organic compounds in the breath of normal humans. J Chromatogr B Biomed Sci Appl. 1999, 729 (1-2): 75-88. 10.1016/S0378-4347(99)00127-9.

Phillips M, Boehmer JP, Cataneo RN, Cheema T, Eisen HJ, Fallon JT, Fisher PE, Gass A, Greenberg J, Kobashigawa J, et al: Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). J Heart Lung Transplant. 2004, 23 (6): 701-708. 10.1016/j.healun.2003.07.017.

Phillips M, Boehmer JP, Cataneo RN, Cheema T, Eisen HJ, Fallon JT, Fisher PE, Gass A, Greenberg J, Kobashigawa J, et al: Prediction of heart transplant rejection with a breath test for markers of oxidative stress. Am J Cardiol. 2004, 94 (12): 1593-1594. 10.1016/j.amjcard.2004.08.052.

Arthur CL, Pawliszyn J: Solid-Phase Microextraction with Thermal-Desorption Using Fused-Silica Optical Fibers. Analytical Chemistry. 1990, 62 (19): 2145-2148. 10.1021/ac00218a019.

Pawliszyn J: Solid Phase Microextraction: Theory and Practice. 1997, New York: Wiley-VCH

Grote C, Pawliszyn J: Solid-phase microextraction for the analysis of human breath. Anal Chem. 1997, 69 (4): 587-596. 10.1021/ac960749l.

Schwarz K, Filipiak W, Amann A: Determining concentration patterns of volatile compounds in exhaled breath by PTR-MS. J Breath Res. 2009, 3: 027002-10.1088/1752-7155/3/2/027002. (027015pp)

Hansel A, Jordan A, Holzinger R, Prazeller P, Vogel W, Lindinger W: Proton transfer reaction mass spectrometry: on-line trace gas analysis at the ppb level. Int J Mass Spectrom Ion Processes. 1995, 149/150: 609-619. 10.1016/0168-1176(95)04294-U.

Lindinger W, Hansel A, Jordan A: On-line monitoring of volatile organic compounds at pptv levels by means of proton-transfer-reaction mass spectrometry (PTR-MS) medical applications, food control and environmental research. Int J Mass Spectrom Ion Processes. 1998, 173: 191-241. 10.1016/S0168-1176(97)00281-4.

Lindinger W, Hansel A, Jordan A: Proton-transfer-reaction mass spectrometry (PTR-MS): on-line monitoring of volatile organic compunds at pptv levels. Chem Soc Rev. 1998, 27: 347-354. 10.1039/a827347z.

Schwarz K, Pizzini A, Arendacká B, Zerlauth K, Filipiak W, Schmid A, Dzien A, Neuner S, Lechleitner M, Scholl-Bürgi S, et al: Breath acetone - aspects of normal physiology related to age and gender as determined in a PTR-MS study. J Breath Res. 2009, 3: 027003-10.1088/1752-7155/3/2/027003. (027009pp)

Agresti A, Caffo B: Simple and effective confidence intervals for proportions and differences of proportions results from adding to successes and two failures. The American Statistician. 2000, 54 (4): 280-288. 10.2307/2685779.

Lumb A: Nunn's Applied Respiratory Physiology. 2005, Oxford: Butterworth-Heinemann

Filser JG, Csanady GA, Denk B, Hartmann M, Kauffmann A, Kessler W, Kreuzer PE, Putz C, Shen JH, Stei P: Toxicokinetics of isoprene in rodents and humans. Toxicology. 1996, 113 (1-3): 278-287. 10.1016/0300-483X(96)03457-9.

Csanady GA, Filser JG: Toxicokinetics of inhaled and endogenous isoprene in mice, rats, and humans. Chem Biol Interact. 2001, 135-136: 679-685. 10.1016/S0009-2797(01)00204-6.

Zhao J, Zhang RY: Proton transfer reaction rate constants between hydronium ion (H3O+) and volatile organic compounds. Atmos Environ. 2004, 38 (14): 2177-2185. 10.1016/j.atmosenv.2004.01.019.

Thông tin
Thông tin xuất bản

BMC Cancer

Tập 9 Số 1

Thông tin tác giả